Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We also believe that our more focused and strategic approach better positions us to enhance value for shareholders |
| We believe this unique design enables our CAB-CTLA-4 antibody to have the potential to deliver efficacy with a manageable safety and tolerability profile |
| In treatment-refractory patient populations, there are encouraging early responses in the Phase II melanoma study at the Q2W dosing regimen that are consistent with our Phase I expansion study |
| In addition to the consistent differentiated safety profile, we continue to observe clinical benefit in patients, including multiple PRs at a TmPS score of 1% |
| And that's in third line, so we think we'll do even better in second line |
| BioAtla is the inventor and leader in the development of novel therapies using a proprietary conditionally active biologics CABS platform with improved selectivity for attacking tumor cells while avoiding healthy cells, thereby addressing critical unmet needs in oncology to improve patients' lives |
| As a result, we believe that there are mutually compelling opportunities for forming one or more strategic collaborations with major pharmaceutical partners that both accelerate and maximize our therapeutics opportunity |
| We observed that the CAB platform continues to demonstrate compelling clinical efficacy and safety across multiple therapeutic targets and formats in the most challenging cancer cases |
| So quite encouraging at this stage |
| But hopefully, that's helpful, and we think it's very promising |
| We believe that forming one or more strategic collaborations with major pharmaceutical partners can accelerate development of selected assets and maximize their market opportunities |
| There are also encouraging early responses in head and neck cancer at 2Q3W also with a new PR observed in ROR2 TmPS negative patient, which makes two out of two responses at the 2Q3W dose across Phase I and Phase II |
| As previously communicated, our highest priority is to deliver innovative life-changing therapies to cancer patients with significant unmet medical needs |
| And I get why -- I would be asking the same question Arthur that you are because this is one of those pan-cancer opportunities with very high selectivity with a very potent mechanism that is enabled by CABS with this T-cell recruiting capability |
| So we think that this has a chance of broadening the actual market opportunity here |
| And finally, I'm pleased to report our progress with the medical and scientific communities with an additional abstract on BA3011 alone or in combination with nivolumab in patients with lung cancer, which was accepted for presentation at the upcoming IASLC conference this December |
| But as part of our prioritization process, which is -- has to factor in a very encouraging data out of the actual lung data |
| Beginning with our CAB-CTLA-4 antibody, BA3071, which is applicable in areas of high unmet need in treatment-refractory patients represents a sizable commercial opportunity |
| In addition to advancing collaboration discussions, we will continue to advance selected CAB assets that can address significant unmet medical needs in order to maximize shareholder value |
| And I think it's early, but all good so far |
| And so we're very eager to push it along |
| Taken together, we continue to believe that BA3011 is an active agent in treatment-refractory tumors and has the potential to become a first-in-class treatment for a significant number of patients who experienced the failure of at least one prior line of therapy |
| His regulatory interaction experience coupled with his known track record of leading cross-functional teams will be instrumental as we advance clinical development efforts and strategic collaborations |
| Earlier this quarter, we also received verbal FDA feedback that we believe is supportive of a registrational path forward for BA3011 in lung cancer |
| In regards to other bone and soft tissue sarcoma cohorts, we are pleased to have yet our internal Go criteria for several sarcoma subtypes, including synovial sarcoma, liposarcoma and osteosarcoma |
| Take care now and all the best |
| We have encouraging Phase I observations to date, and we continue to follow these patients progress |
| In particular, a safety profile with less immune-related adverse events across multiple tumor types may allow patients to stay on therapy for longer and achieve clinical benefit from this important immunotherapy |
| The ROR2 melanoma indication recruitment has been assisted by enrolling target-agnostic patients, followed by a retrospective target expression analysis, both of which resulted in quicker enrollment and the opportunity to target a larger melanoma patient population |
| Brian Cheng Great |
| Statement |
|---|
| Of note, AXL expression in lung cancer defines a particularly poor prognostic group |
| It also, because of the AXL being a poor prognostic indicator, meaning the patients have a very difficult time, at least maybe some of the most difficult patients to treat, remembering that our entire study, all the patients had a median of three prior lines of treatment, and they were AXL positive |
| But for the moment, we're going to look to see if we can have a similar or even potentially greater impact and ones that are less than 1% given that poor prognostic indication of AXL expression -- with AXL expression |
| Also, these patients had experienced the failure of a median of three prior lines of therapy |
| So we think a cross-trial comparison is a little difficult when you -- when the others haven't gone into an actual positive data set |
| Net loss for the third quarter ended September 30, 2023 was $33.3 million compared to a net loss of $25.8 million for the same quarter in 2022 |
| So there's a real -- there's some significant likelihood that we're going to see responses below the 1%, and we're going to find that out and add that to the data sets, which could have a substantial impact on the market opportunity of our drug |
| So it's going to move quickly, and we'll have a lot more to talk about it, and we have only seen positive things so far |
Please consider a small donation if you think this website provides you with relevant information